Canadian Association for Porphyria

Porphyria Treatment

Special Access Programme (SAP) - Health Canada

The Special Access Programme (SAP) provides access to nonmarketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.

Canadians with porphyria can access two treatments through the SAP - Normosang or Panhematin for Hepatic porphyria - Acute Intermittent Porphyria, Variegate Porphyria and Hereditary Coproporphyria; and Scenesse for Erythropoietic Protoporphyria.

Information on the Special Access Program (SAP):

SAP Fact Sheet

SAP Special Access Request Form A

SAP Future Use Request Form B

SAP Follow-up Form C

Notice: Guidance for Industry and Practitioners: Special Access Programme for Drugs Guidance Document

Source: Health Canada

Last Updated: 10/January/2017 

Medical Disclaimer

Care has been taken to ensure that the information on this website is accurate at the time of publication. This information is, however, intended for general guidance only and is not meant to substitute consultation from a recognized health professional. The Canadian Association for Porphyria/Association Canadienne de Porphyrie disclaims for itself and for the author of this information, all responsibility for any mis-statements or for consequences of actions taken by any person while acting on information contained herein. Physicians and patients must make their own decisions about therapy according to the individual circumstances of each case.

Powered by Wild Apricot Membership Software